Dr. Lal Path Labs working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

27.31×	27.31×	27.82×	28.75×	35.24×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
13.13×	13.13×	12.27×	12.15×	14.13×
129.52×	129.52×	146.08×	138.55×	123.85×
−89.08×	−89.08×	−105.99×	−97.65×	−74.48×
2.59×	2.48×	2.56×	3.37×	4.01×
0.94×	0.94×	0.95×	0.92×	0.85×
1.25×	1.25×	1.16×	1.48×	1.89×
0.81×	0.81×	0.82×	0.88×	0.93×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health

₹ CrorePeersMETROPOLIS VIJAYA THYROCARE NATCOPHARM NEULANDLAB NH COHANCE SAILIFEMcap ₹32,040 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	35.24	28.75	27.82	27.31	27.31
Receivable Days (DSO)	14.13	12.15	12.27	13.13	13.13
Payable Days (DPO)	123.85	138.55	146.08	129.52	129.52
Cash Conversion Cycle (days)	-74.48	-97.65	-105.99	-89.08	-89.08
Working Capital Turnover	4.01	3.37	2.56	2.48	2.59
Asset Turnover	0.85	0.92	0.95	0.94	0.94
Cash Conversion (CFO/Net Income)	1.89	1.48	1.16	1.25	1.25
CFO/EBITDA	0.93	0.88	0.82	0.81	0.81

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.